SLXN Silexion Therapeutics Corp.

NASDAQ
$0.42

Silexion Therapeutics Corp. (SLXN) is expected to report earnings on November 13, 2026, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of +1.4% since its last earnings release on August 14, 2026.

Silexion Therapeutics Reported Earnings
Friday, August 14, 2026 · 8:45 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 8:30 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Silexion Therapeutics Corp.

Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. Silexion Therapeutics Ltd., formerly known as Biomotion Sciences, is based in NEW YORK.

Sector

Healthcare

Industry

Biotechnology